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Abstract
Rationale and Objectives—To investigate for differences in metabolic concentrations and 
ratios between patients with systemic lupus erythematosus (SLE) without (group SLE) and those 
with neurological symptoms (group NPSLE) compared to a healthy control (group HC) in three 
normal-appearing brain regions: the frontal white matter, right insula (RI), and occipital gray 
matter and whether changes in any of the metabolites or metabolic ratios are correlated to disease 
activity and other clinical parameters.
Materials and Methods—Twenty patients with SLE (18 women and 2 men, age range 23.4–
64.6 years, mean age 43.9 years), 23 NPSLE patients (23 women, age range 23.7–69.8 years, 
mean age 42.4 years), and 21 HC (19 women and 2 men, age range 21.0–65.7 years, mean age 
43.4 years) were included. All subjects had conventional brain magnetic resonance imaging 
and 1H single-voxel spectroscopy, clinical assessment, and laboratory testing.
Results—NPSLE patients had significantly reduced N-acetylaspartate (NAA)/creatine compared 
to HC (P = .02) and SLE patients (P = .01) in the RI. Lower glutamine/creatine levels were also 
detected in RI in both patient groups and in frontal white matter in NPSLE patients compared to 
HC (P = .01, P = .02). NAA/Cr ratio in the RI was significantly negatively correlated with the 
Systemic Lupus Erythematosus Disease Activity Index (r = −0.41; P = .008), and patients with 
active SLE symptoms also had a trend toward lower NAA/creatine ratios (1.02 vs 1.12; P = .07).
Conclusions—The present data support previous findings of abnormal metabolic changes in 
normal-appearing regions in the brain of both SLE and NPSLE patients and raise the possibility 
that especially NAA, glutamine, and glutamate may be additional biomarkers for cerebral disease 
activity in SLE patients as these early metabolic changes occur in the brain of SLE patients before 
neurologic and imaging manifestations become apparent.
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Systemic lupus erythematosus (SLE) is a chronic inflammatory, immune-mediated disease 
that affects 0.1% of the general population. Neuropsychiatric SLE (NPSLE) is a severe and 
life-threatening condition, reported to occur in 25% to 70% of patients with SLE (1,2) and 
associated with increased morbidity and mortality (3,4). Clinically, NPSLE can present with 
acute symptoms such as stroke, seizures, or movement disorders, which are usually 
diagnosed promptly and reliably. However, many individuals with SLE develop a variety of 
other symptoms, including headaches, psychosis, cognitive dysfunction, depression, or other 
less specific symptoms, and the diagnosis and attribution to NPSLE are much less certain. 
The wide variation in NSPLE incidence emphasizes the need for better diagnostic tests. 
Clinical manifestations of NPSLE include headaches, stroke, myelopathy, seizures, 
psychosis, confusional states, and cognitive impairment but also peripheral manifestations 
such as cranial neuropathies and inflammatory demyelinating polyradiculoneuropathies. 
Patients with concomitant antiphospholipid antibodies are at additional risk for 
neuropsychiatric events. Lupus patients are also at increased risk for a wide range of central 
nervous system (CNS) events related to immunosuppressive therapy, including infection and 
drug toxicity.
Magnetic resonance imaging (MRI) is frequently used to diagnose or exclude main brain 
alterations and has become part of the routine clinical workup of such alterations (5). 
Abnormal conventional MRI findings are common in both SLE and NPSLE patients (6,7) 
and range from nonspecific small punctate focal lesions in white matter (WM) (present in 
the majority of NPSLE patients but not specific) to more severe findings such as cortical 
atrophy, ventricular dilation, cerebral edema, cerebral infarctions, and intracranial 
hemorrhage (8). These findings are attributed to different mechanisms, including 
thrombosis, vasculopathy, and antibody-mediated neuronal injury (9).
Animal models suggest that there is evidence that inflammatory processes in the CNS might 
lead to neuronal loss (10), as well as impaired neurogenesis/neuronal migration (11) in SLE. 
Although clinical assessment is the cornerstone of the NPSLE diagnosis, this diagnosis can 
be difficult to make and is frequently presumptive. Previous MR spectroscopy (MRS) 
studies have demonstrated changes of the brain metabolites in SLE patients in both 
abnormal- and normal-appearing WM. Common metabolites previously evaluated are N-
acetylaspartate (NAA), which is considered a marker for neuronal viability and function, 
creatine (Cr) a marker of cell energy and cell metabolism, and choline (Cho). Cho molecules 
detected in 1H-MR spectra are largely from phosphorylcholine and 
glycerophosphorylcholine, which are precursors to cell membrane biosynthesis and 
breakdown, respectively. Other MRS markers that are of interest in the SLE population 
include myoinositol as well as glutamate (Glu) and glutamine (Gln) and these combined 
(Glx). Most of these previous reports have showed a decline in the NAA/Cr ratio and an 
increase in the Cho/Cr ratio in periventricular WM and basal ganglia (12–14), while others 
have reported a more widespread significant decrease in the NAA/Cho and NAA/Cr ratios 
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and a significant increase in the Cho/Cr ratio (12,13,15–18). A recent study has 
demonstrated changes in the Gln–Glu complex in the hippocampus correlating to memory 
dysfunction in SLE patients without neuropsychiatric symptoms (19). To our knowledge, 
there are no previous reports on different metabolic ratios or concentrations of these 
metabolites specifically in the insula region.
The purpose of this study was to investigate if differences in metabolic concentrations and 
ratios exist between patients with SLE and healthy controls (HC), as well as between SLE 
patients with neurologic symptoms (group NPSLE) and those without (group SLE), in three 
specific brain regions: the frontal WM (FWM), right insula (RI; a region included in the so-
called pain matrix and commonly evaluated in fibromyalgia patients and other pain 
conditions) (20), and occipital gray matter (OGM; our control region), a good location for 
cortical gray matter evaluation (21). The SLE patients may, among their many symptoms, 
complain of diffuse pain (similar to fibromyalgia patients). Therefore, we decided to study 
the insula region to compare our findings to those previously found in fibromyalgia patients. 
Also, in this study we evaluate not only the basic metabolites NAA, Cho, myoinositol, and 
Cr but also Glu, a neurotransmitter, and Gln, a molecule used in Glu shuttle between 
neurons and glia. The metabolite Glu is often elevated in pain conditions like fibromyalgia 
and has shown to be positively correlated to the severity of pain (22). The Glu + Gln/Cr ratio 
has shown to be decreased in the right hippocampus in SLE patients and negatively 
correlated to memory function (19). The second aim was to investigate if any of the 
observed metabolite differences were correlated with disease activity and other clinical 
parameters. Our third aim was to follow the NPSLE patients longitudinally to see if any 
changes in conventional MRI and/or metabolic activity occurred following treatment.
MATERIALS AND METHODS
Participants
Twenty-three consecutive patients (23 women, age range 23.7–69.8 years, mean 42.4 years), 
with acute NPSLE, defined as one or more neuropsychiatric manifestations within 2 weeks 
before inclusion in the study and without a previous history of NPSLE; 20 consecutive 
patients with SLE (18 women and 2 men, age range 23.4–64.6 years, mean age 43.9 years), 
without history of or current neuropsychiatric symptoms; and 21 HC (19 women and 2 men, 
age range 21.0–65.7 years, mean age 43.4 years) were initially enrolled for this prospective 
3-T MRI study. In addition, longitudinal MRI examinations were performed at 3 and 6 
months after initial MRI examination in 13 of the 23 NSPLE patients. The classification of 
NPSLE was based on the 19 American College of Rheumatology (ACR) 1999 case 
definitions (23,24). To participate in the study, individuals needed to fulfill four or more of 
the ACR classification criteria and present within 2 weeks of the initial neuropsychiatric 
event. Informed consent was obtained for all participants, and the study was approved by the 
University of Michigan Institutional Review Board. Exclusion criteria included drug or 
alcohol abuse, diabetes, stroke, a diagnosis of fibromyalgia, and renal insufficiency.
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Conventional MRI and Proton MRS
All subjects had conventional MRI pre– and post–intravenous (IV) contrast administration 
with following sequences: T1-weighted three-dimensional turbo field echo images pre– and 
post–IV contrast enhancement, diffusion-weighted imaging, axial T2-weighted, and FLAIR 
(fluid-attenuated inversion recovery) images. All subjects had single-voxel 1H-MRS (SVS), 
using the following parameters—pointed-resolved spectroscopy, repetition time (TR) 2000 
ms, echo time (TE) 30 ms, voxel size 2 × 2.2 cm—performed at baseline and at 3 and 6 
months after baseline for the NPSLE patients. In this study, we have chosen the SVS 
technique with short TE of 30 ms, as this technique result in a spectrum with more 
metabolite peaks, such as myoinositol and Gln-Glu, which are not detected with long TE, 
and also allow a more accurate quantification of the metabolites. The individual volumes 
were placed in the following regions of interest: FWM, RI, and OGM (Fig 1). All MRI and 
MRS examinations were performed on a Philips 3-T Achieva MR scanner (Philips MRI 
system, Best, Netherlands), with an eight-channel sensitivity encoding head coil. The 
metabolite concentrations of NAA, total Cho (tCho), total creatine (tCr), Glu, and Gln, and 
the presence of lactate (Lac) were analyzed. The ratios NAA/Cr, Cho/Cr, Gln/Cr, and 
myoinositol/Cr were calculated. The data from the SVS were analyzed on a computerized 
analysis system: the LC model (25). Metabolite concentrations were used only for statistical 
analysis from the LC model if the Cramér–Rao bounds were less than 20%.
Clinical Outcomes
All the patients and the HC had standardized clinical and neurological examinations 
including medical history, demographics, physical exam, standard laboratory assessment, 
and a Mini-Mental State Examination (MMSE) (26). MMSE evaluation in NPSLE patients 
presenting with acute confusional state, who could not be evaluated at the time of admission, 
was delayed. However, all patients were able to perform the test within 96 hours of 
treatment. SLE and NPSLE patients underwent required laboratory tests to determine 
disease activity by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 
(27) as well as antiphospholipid antibody status. SLE was considered active with an 
SLEDAI score greater than 3. Disease duration was defined as the time between the 
diagnosis of SLE and the day of the MRI. CNS manifestations were divided into central and 
peripheral following ACR case definitions. Cumulative damage in both patient groups was 
assessed using the Systemic Lupus International Collaborating Clinics/ACR Damage Index 
(SLICC) (4) at the time of MRI acquisition.
MR Image Evaluation
The conventional MR images were evaluated by an experienced neuroradiologist (blinded to 
the patient history) for any signal abnormalities, hemorrhage, acute ischemic events, old 
infarcts, focal lesions, and focal or general atrophy and for any additional lesions not related 
to SLE. Lesion burden in form of WM T2/FLAIR hyperintensive lesions was defined as 
mild (1–5 WM lesions), moderate (5–10 WM lesions), or severe (>10 WM lesions). In 
addition to the conventional images, SVS MRS was analyzed as mentioned earlier. Any 
clinically relevant findings on structural MRI were reported to the patient’s primary 
physician.
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With respect to age, disease duration, and SLEDAI and SLICC scores, as well as most lab 
data (except from the lupus anticoagulant), groups were compared using an analysis of 
variance (for comparison of all three groups). Post-hoc t-tests were used to determine which 
group—SLE, NPSLE, or HC—displayed different values. For the longitudinal assessment of 
changes in metabolite levels, we used a repeated-measures general linear model for each 
metabolite and compared baseline, 3-month, and 6-month follow-up values. Post-hoc paired 
t-tests were performed to determine which of the three periods displayed statistically 
different values. Nonparametric tests (χ2) were applied to compare gender distribution, 
smoking history, cardiovascular risk factors, and the lupus anticoagulant confirmation 
measure (Lac). Evidence of any Lac resulted in a score of 1; the absence of Lac resulted in a 
score of 0.
RESULTS
Clinical Manifestations, Disease Severity, and Serological Data
Demographic data and disease activity are presented in Table 1. Disease duration was 
slightly longer in the NPSLE group (mean 10.5 years, range 2–25 years, SD 6.8 years) 
compared to the SLE group (9.4 years, range 3–19 years, SD 5.2 years); however, this 
difference did not achieve significance. Disease activity was significantly higher in the 
NPSLE group, by SLEDAI score (P < .001). No differences were found in SLICC scores or 
in MMSE scores between the groups (Table 1). NPSLE patients had higher levels of anti–β2-
glycoprotein I immunoglobulin (Ig)A (P < .05) than SLE patients. NPSLE patients also 
showed a trend to have higher levels of double-stranded DNA antibodies (anti–double-
stranded DNA; P < .06). Other antiphospholipid antibodies (anti–β2-glycoprotein I IgG/IgM, 
anticardiolipin antibody, and Lac) did not differ significantly between the two patient groups 
(Table 2). In 3 of the 23 NPSLE patients, only parts of the laboratory data could be 
reviewed, due to some data errors; the remaining 20 NPSLE patients had all their serology 
data reviewed. A total of 17 diffuse neuropsychiatric manifestations and 7 focal 
manifestations were present in the NPSLE group, with 18 central and 2 peripheral events. 
The following manifestations were seen: psychosis (3 patients), transverse myelitis (1 
patient), acute confusional state (10 patients), headaches (3 patients), depression (1 patient), 
cerebrovascular disease (6 patients), and cranial nerve deficit (1 patient). A few NPSLE 
patients had several different events that were both focal and diffuse at the same time. 
Nineteen of 23 patients were acutely treated with IV and/or oral steroids. One patient was 
treated exclusively with selective serotonin reuptake inhibitors. Thirteen patients required 
the addition of immunosuppressive drugs as well.
Conventional MRI
The conventional MRI demonstrated mild or moderate diffuse brain atrophy in 30% of the 
patients (21 of 64). Mild atrophy was seen in 10 SLE patients, 7 NPSLE patients, and 1 HC 
subject. Moderate atrophy was present in 2 SLE patients and in 1 NPSLE patient. One 
patient with SLE had a wedge-shaped area of encephalomalacia in the right frontal lobe, and 
1 patient with NPSLE had an old infarct in the right frontal lobe. Mild lesion burden was 
seen in 70% of the SLE patients (14 of 20), moderate in 15% (3 of 20), and severe in 5% (1 
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of 20). Mild lesion burden was seen in 52.2% of the NPSLE patients (12 of 23), moderate in 
21.7% (5 of 23), and severe in 13% (3 of 23). In the HC group, 6 patients had mild lesion 
burden, 1 patient had moderate lesion burden, and 1 patient had severe lesion burden. 
Incidental findings were noted of seven venous angiomas, three pineal cysts, two arachnoid 
cysts, and one aneurysm of the right internal carotid artery.
The conventional MRI demonstrated a few new lesions at the 3-month follow-up 
examination: new focal WM lesions in two NPSLE patients and acute ischemia in one 
NPSLE patient. No additional changes were seen at the 6-month follow-up.
MRS
Overall, the quality of the spectra in the three different locations was good. In the HC group, 
one of the spectra in the FWM, two in the RI, and two in the OGM were excluded due to 
poor quality of the spectra. In SLE patients, five of the spectra in the FWM and one in the RI 
were excluded due to poor quality of the spectra, and in the NPSLE patients, three of the 
spectra in the OGM were excluded due to poor quality of the spectra.
Metabolic Ratios
A one-way analysis of variance of the SVS MRS data revealed that the NAA/Cr ratio within 
the RI was significantly different across groups (mean [SD]: HC 1.12 [0.08], SLE 1.13 
[0.16], NPSLE 1.03 [0.16]; P = .02). Post-hoc analyses indicated that this finding was due to 
lower NAA/Cr levels in the NPSLE patients. This group had significantly reduced NAA/ Cr 
compared to HC (P = .02) and SLE patients (P = .01). Gln/Cr levels within the RI were also 
found to differ across all three groups (mean [SD]: HC 0.60 [0.37], SLE 0.38 [0.13], NPSLE 
0.40 [0.12]; P = .02). Post-hoc analysis revealed that this was due to lower Gln/Cr levels in 
both patient groups (SLE versus HC: P = .01, NSPLE versus HC: P = .01). No other 
metabolites in the insula, including myoinositol/Cr, showed differences across groups.
Within the FWM, Gln/Cr ratios differed across groups (mean [SD]: HC 0.64 [0.42], SLE 
0.42 [0.31], NPSLE 0.36 [0.16]; P = .05). Post-hoc analyses indicated that this finding was 
due primarily to lower levels of Gln/Cr in the NPSLE group compared to HC (P = .02). The 
SLE group had a trend toward lower Gln/Cr in the FWM compared to controls (P = .08). 
Glu/Cr and Cho/Cr also had trends toward differing metabolite levels across group, but these 
were not significant (Cho/Cr: P = .07; Glu/Cr: P = .08). No other metabolites in the FWM 
regions, including myoinositol/Cr, showed differences across groups. Furthermore, no other 
metabolites showed significant differences across groups in the OGM. The different 
metabolic ratios from the three different regions were evaluated, and their P values are 
presented in Table 3. Figure 2 shows the alterations in metabolite ratios in the RI region 
among the groups.
Metabolic Concentrations
The following metabolites were evaluated: NAA, tCho, tCr, Glu, and Gln. Metabolic 
concentration as given in institutional arbitrary values showed some significant differences 
between the groups. The tCho in the FWM is different across groups (P = .008). Post-hoc 
tests revealed that tCho is reduced in SLE (P = .004) compared to HC and reduced in SLE 
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compared to NPSLE (P = .008). No significant differences in tCho were seen between 
NPSLE and HC (P > .10; mean [SD]: SLE 1.28 [0.578], NPSLE 1.63 [0.27], HC 1.68 
[0.30]). NAA in the RI was different across groups (P = .009). Post-hoc test revealed that 
NAA was significantly reduced in NPSLE compared to HC (P = .003). No significant 
differences were seen between SLE and HC (P = .26); however, there was a trend for lower 
NAA in the NPSLE group compared to the SLE group (P = .06; mean [SD]: NPSLE 6.47 
[0.63], SLE 6.80 [0.50], HC 6.99 [0.43]). The tCr levels had a trend to higher values for 
NPSLE vs. SLE (P = .09) but were not significantly different. There were no differences in 
tCr levels between NPSLE and HC in the insula.
Metabolite Ratios and SLEDAI
The difference between the SLEDAI scores for the SLE patients (2.1 ± 2.5) was significantly 
different from the NPSLE patients’ SLEDAI scores (11.3 ± 6.2; P < .01). When the SLE and 
NPSLE groups were combined, the NAA/Cr ratio in the RI was significantly negatively 
correlated with the SLEDAI score (r = −0.41, P = .008). Patients with lower NAA/Cr ratios 
had higher SLEDAI scores. This relationship was due in part to heavy weighting of 
neuropsychiatric symptoms in the SLEDAI since patients with SLEDAI scores reflecting 
neurological involvement had a trend toward lower NAA/Cr (mean [SD]: nonneurological 
1.11 [0.16], neurological 1.01 [0.18]; P = .10). Furthermore, when SLE and NPSLE groups 
were analyzed on the basis of active SLE symptoms, patients with active symptoms also had 
a trend toward lower NAA/Cr ratios (mean [SD]: inactive 1.12 [0.15], active 1.02 [0.18]; P 
= .07). No significant relationships or trends were found between the RI Gln/Cr or the FWM 
NAA/Cr, Cho/Cr, or Gln/Cr ratios and other disease symptoms.
Longitudinal Follow-up of Metabolic Ratios
Fourteen of the 23 NPSLE patients completed the longitudinal follow-up and were scanned 
at 3 and 6 months following the baseline session. Over the course of these sessions, the 
NAA/ Cr level within the RI increased significantly (NAA/Cr mean [SD]: baseline 1.03 
[0.17], 3 months 1.10 [0.12], 6 months 1.17 [0.16]; P = .035). Post-hoc analysis indicated a 
significant increase between baseline and 6 months (P = .008). No other significant changes 
in metabolic ratios occurred over time. The metabolic ratios in the RI region at the different 
time points in the NSPLE group are presented in Table 4. The longitudinal changes in the 
different metabolic ratios in the NPSLE group are presented in Figure 3.
The SLEDAI score significantly decreased over the course of 6 months (13.07 [6.20]; 3.80 
[2.86]; P = .001); however, the change in SLEDAI was not correlated with changes in 
NAA/Cr (r = 0.12; P = .68) (Fig 4).
DISCUSSION
NPSLE is a spectrum of disorders that may be severe and life-threatening and that occur in 
some SLE patients. The pathogenesis of NPSLE is poorly understood with a wide range of 
clinical symptoms and various patterns on conventional MRI. Recently, an immune-
mediated pathogenesis has been suggested (28). Clinically, NPSLE can present as acute 
symptoms such as stroke, seizures, or movement disorders, which are usually diagnosed 
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promptly and reliably. However, many individuals with SLE develop a variety of other 
symptoms including headaches, psychosis, cognitive dysfunction, depression, or other less 
specific symptoms, and the diagnosis and attribution to NPSLE are much less certain. MRI 
has been used extensively in the evaluation of neuropsychiatric NPSLE and has proved to be 
more sensitive than computed tomography (29).
Previous 1H-MRS studies performed on 1.5-T scanner in SLE and NPSLE patients have 
reported decreased NAA/Cr and increased Cho/Cr in the periventricular WM and basal 
ganglia (5,13,15,16,30,31), while a few others (14) reported a significant decrease in the 
NAA concentration and increase in the Cho concentration. None of these previous studies 
have demonstrated these findings specifically in normal-appearing WM in the anterior FWM 
or in the RI region on a 3-T scanner. Therefore, the present study is focused, in contrast to 
the previous SVS MRS studies, on metabolic changes in areas of the brain that appear 
normal on conventional MRI with no signal abnormalities on T2 and FLAIR images or focal 
lesions in the analyzed volume of interest. In contradiction to previous reports, the present 
study showed a decline in tCho in normal-appearing anterior FWM in the SLE and NPSLE 
patients compared to HC (13–15). More interestingly, tCho was significantly reduced in SLE 
patients compared to NPSLE patients (P = .008) and there was also a trend toward reduction 
of the Cho/Cr between the groups even if not significant (P = .07). This may indicate that 
early metabolic changes occur in the brain of SLE patients before neurological and imaging 
manifestations become apparent. This assumption is also supported by our recent findings of 
significant decreased fraction anisotropy in several regions in the prefrontal WM in both 
SLE and NPSLE patients (32).
When neurological manifestations are finally present, an increase in Cho might be expected 
as Cho is suggested to represent a cell membrane turnover marker that can be seen in 
demyelization, remyelination, inflammation, and gliosis (33). Gln/Cr was also found to be 
decreased in both SLE and NPSLE patients compared to HC with a steeper decline in 
Gln/Cr in the NPSLE group. Significantly lower Gln/Cr levels within the RI were seen in 
both SLE and NPLSE patients compared to HC. In addition, NPSLE patients demonstrated 
significantly lower Gln/Cr ratios in the anterior FWM compared to HC (P = .02), and the 
SLE patients had a strong trend toward lower Gln/Cr in the FWM compared to HC. Also, 
Glu/Cr showed a trend to be lower in SLE and NPSLE patients, but these findings were not 
significant. These changes could be explained as indicators of the acute changes in brain 
tissue on a microscopic level, as no obvious abnormalities in the evaluated reviewed regions 
were seen on conventional MRI, at the time patients present with clinical neurological 
manifestations. The decline in Gln/Cr in the SLE group, less pronounced, could be 
explained as subclinical changes that may or may not fully manifest clinically. The present 
finding of decreased Gln and the trend to lower Glu in both SLE and NPSLE patients in the 
insula and frontal WM regions have not been demonstrated previously in SLE and NPSLE 
patients. However, previous studies have demonstrated changes in Glu and Gln in patients 
with, for example, fibromyalgia (20,22) and in patients with myofascial pain (34). Our 
present findings in the SLE population are in contrast to the findings seen in patients with 
fibromyalgia. These studies demonstrated an increase in Glu and Gln in the insular region in 
fibromyalgia patients, and the levels were correlated to the patient complaints of pain 
(20,22). A decrease in Glu was seen in the insular region in patients with myofascial pain 
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after pain testing and the Gln levels were related to reported pain (34). In the present study, 
our initial thought was to examine the patients for pain sensitivity, but this was found to be 
logistically impossible and only the first few patients had pain testing. However, none of the 
included patients complained of pain, and we excluded patients who fulfilled the criteria for 
fibromyalgia or had chronic pain disorders. Our findings of decrease in Glu, a 
neurotransmitter, and Gln, a molecule used in Glu shuttle between neurons and glia, could 
potentially be explained by the neuronal loss with a decrease of synapses and neurons. Our 
findings of changes in Gln and Glu in SLE and NPSLE patients are not unique. Previous 
studies have shown a correlation between the gln–glu complex (Glx)/Cr ratio in the 
hippocampus and higher memory functions. They found that lower Glx/Cr ratios and 
NAA/Cr ratios were associated with lower visual memory in SLE patients without 
neuropsychiatric symptoms (19). In the present study, we did not specifically evaluate 
cognitive performance to the Gln and Glu levels. Certainly, additional studies on the roles of 
Glu and Gln and of cognitive performance in SLE and NPSLE patients are needed.
A significant decrease in the NAA/Cr ratio and in the NAA concentration were present in 
the NPSLE patients compared to HC and SLE patients in a previously not evaluated region 
of the brain in SLE patients—the right insular region. Our findings of decreased NAA/Cr 
and NAA concentrations are in concordance with previous studies (12–15). Decline in NAA 
concentration can be seen as evidence of neuronal loss and neuronal damage. However, 
several recent studies indicate that these decreases in regional NAA levels can also represent 
reversible neuronal or mitochondrial dysfunction (35). Therefore, quantification of NAA or 
calculation of NAA/Cr ratio by MRS might be a valuable tool to assess neuronal dysfunction 
and the effects of potential neuroprotective therapies (ie, the persistence over time of low 
NAA versus normalization of levels after treatment can be used as a marker for treatment 
response).
When the SLE and NPSLE groups were combined, the NAA/Cr ratio in the RI was 
significantly negatively correlated with the SLEDAI score, so patients with lower NAA/ Cr 
ratios had higher SLEDAI scores. This relationship was due in part to neurobiological 
symptoms since patients with SLEDAI scores reflecting high neurobiological involvement 
had a trend toward lower NAA/Cr. As could be expected, our study demonstrates that 
patients with active SLE disease and active symptoms had a trend toward lower NAA/Cr 
ratios (P = .07) and significantly lower NAA concentration indicating axonal dysfunction. 
Similar findings of reduced NAA in SLE patients with active disease have been seen in other 
regions of the brain (15,36). They have also demonstrated that the relative reduction in NAA 
in SLE patients might be transient, and it is probably dependent on disease activity, as NAA 
will increase after treatment and will change in patients going from having active to inactive 
disease (15,36). The role that disease activity might have on cerebral metabolic activity is 
supported by previous studies that have demonstrated changes in cerebral vascularity in SLE 
patients with active disease with elevated cerebral blood flow, cerebral blood volume, and 
mean transit time compared to HC subjects (37–39). Interestingly, despite a correlation 
between SLEDAI and the NAA at baseline, there were no correlation between the SLEDAI 
score improvement and the increase in NAA/Cr over time. A possible explanation is that the 
SLEDAI measures are different parameters of lupus disease activity—not only CNS 
manifestations but also other organ and system involvement, as well as laboratory 
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parameters to express the individual patient’s lupus activity 10 days prior to the MRS 
examination. Whereas the NAA represents only the metabolic changes due to neural or 
mitochondrial dysfunction in the brain over time.
Our study has limitations such as the limited patient cohort, the lack of some laboratory data 
in three of the 23 NPSLE patients, and the limited number of SVS voxels placed. Notably, 
the main goal was to evaluate a previously nonimaged region—the insula. Another possible 
limitation is that we used, as in so many other studies in this topic, the LC model software 
for analysis of the spectra. The LC model fitting algorithm uses the multiple peaks 
contributing to an individual metabolite spectrum to estimate the tissue content of each 
metabolite. In our study, all metabolites showed good reliability of fit as judged from the 
average Cramer-Rao lower bounds (<20%). Since previous studies have demonstrated 
certain variability in the NAA/Cr ratios, varying between 3.5% and 8% in different studies 
of healthy individuals and MS patients (40,41), another possible way of measuring could 
have been using coefficient of variance (COV). The benefit of the COV as a measure is that 
the SDs of such metabolites generally increase or decrease proportionally with changes in 
the mean, so that division by the mean removes it as a factor in the variability. The COV is 
therefore a standardization of the SD that allows comparison of variability estimates 
regardless of the overall magnitude of metabolite concentration. In our study, we used the 
SVS technique at one time point for the evaluation of the ratios between the different group. 
In addition, the SDs were similar for the different groups, and we judge that our results and 
significant differences presented would not have been changed using another method of 
analysis.
Another limitation is that we, like many others, use the Cr as denominator in our ratio 
calculation despite our study demonstrating that the tCr levels had a trend to higher values 
for NPSLE patients compared to SLE. In this study, we used the MMSE, a method not 
considered optimal for evaluation of cognitive performance in SLE patients, as mentioned in 
the ACR case definition (24), even if MMSE has been used in SLE studies by other authors.
CONCLUSIONS
These findings again support the role of MRS used with conventional MRI in the evaluation 
of SLE and NPSLE patients. Abnormalities reflecting metabolic changes can be 
demonstrated in both SLE and NPSLE patients even in the absence of morphological lesions 
detectable by conventional MRI. Notably, these data, as well as similar findings reported 
previously, suggest that NAA, Cho, Gln, and Glu may be useful biomarkers for cerebral 
disease activity in SLE patients, as these early metabolic changes occur in the brain of SLE 
patients before neurological and imaging manifestations become apparent, and therefore 
may predict future parenchymal damage.
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Voxel placements (red box) and corresponding metabolic spectra in anterior frontal white 
matter (a,b) and right insula (c,d). Cho, choline; mI, myoinositol; Cr, creatine; NAA, N-
acetylaspartate.
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Bar graph demonstrating the different metabolic ratios in the insula in the systemic lupus 
erythematosus without neurological symptoms (SLE), NPSLE (neuropsychiatric systemic 
lupus erythematosus), and healthy control (HC) groups. NAA, N-acetylaspartate; Glu, 
glutamate; Gln, glutamine; Glx, Glu plus Gln; Cho, choline; mIns, myoinositol.
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Bar graph demonstrating the longitudinal changes of the different metabolic ratios in the 
insula in the neuropsychiatric systemic lupus erythematosus (NPSLE) group. NAA, N-
acetylaspartate; Glu, glutamate; Gln, glutamine; Glx, Glu plus Gln; Cho, choline; mIns, 
myoinositol.
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Scatterplot demonstrating the N-acetylaspartate (NAA)/creatine (Cr) ratios in the insula 
between the three groups (a) and the correlation between the Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) score and the NAA/Cr ratios in the insular region 
neuropsychiatric systemic lupus erythematosus (NPSLE) group (b).
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TABLE 1
Demographic and Disease Severity of the Study Subjects
HC (n = 21) SLE (n = 20) NPSLE (n = 23) P Value
Age 21–66 23–65 23–70 .9
43.9 43.9 42.4
Female (n) 19 (90.5%) 18 (90%) 23 (100%) .3
Age at disease onset (yr) N/A 18–56 13–65 .8
33.4 ± 10.9 32.7 ± 13.5
Disease duration (yr) N/A 3–19 2–25 1.0
9.4 ± 5.2 10.5 ± 6.8
SLEDAI N/A 0–8 1–25 <.001
2.1 ± 2.5 11.3 ± 6.2
SLICC N/A 0–3 0–4 >.2
0.53 ± 1.01 0.95 ±1.12
Mini-Mental State Examination score 32–33 31–33 31–32 >.2
HC, healthy controls; SLE, systemic lupus erythematosus; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index; SLICC, Systemic Lupus Erythematosus International Collaborating Clinics; N/A, not applicable.
Values are range and mean ± SD unless otherwise noted.
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TABLE 2
Laboratory Results and Antibody Data for Study Subjects
HC (n = 21) SLE (n = 20) NPSLE (n = 23) P Value
Hemoglobin 11.6–15.5 10.9–15.8 9.5–14.7 1.162*
13.51/1.066 13.44/1.084 12.92/1.522
WBC 3.9–8.4 2.6–9.2 2.9–17.3 1.868*
5.9/1.272 5.847/1.99 7.25/3.64
Platelet count 214–365 152–405 176–683 .598*
268.6/46.54 265.74/56.58 289.9/110.58
Creatinine 0.6–1.2 0.6–1.50 0.5–1.0 1.961*
0.778/0.157 0.823/0.206 0.755/0.147
Double-stranded DNA N/A 0–28 0–126 .069
9.535/10.22 26.44/35.95
C3 N/A 85–145 65–189 .375
114.94/18.22 122.43/30.15
C4 N/A 7–40 11–39 .880
23.53/8.156 23.95/8.513
ESR N/A 4–27 2–43 .546
14.65/7.566 17.056/14.53
CRP N/A 0–1 0–3.3 .161
0.212/0.237 1.021/2.317
β2G-1 IgG N/A 0–25 0–110 .399
2.267/6.703 7.8/24.34
β2G-l IgM N/A 0–9 0–230 .312
0.867/2.475 14.55/51.404
β2G-l IgA N/A 0–9 0–18 .043
1.0/2.7 4.05/5.094
CAL IgG N/A 0–32 0–40 .438
2.412/7.722 5.1/12.19
CAL IgM N/A 0–13 0–36 .491
1.06/3.172 2.5/7.997
LAC 0–1 0–1 0–1 .078
All negative 4 of 20 positive 1 of 20 positive .239
HC, healthy controls; SLE, systemic lupus erythematosus; NPSLE, neuropsychiatric systemic lupus erythematosus; β2-GPI, β2-glycoprotein I; C3, 
C3 complement; C4, C4 complement; aCL, anticardiolipin antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LAC, lupus 
anticoagulant (binominal); WBC, white blood cell count; N/A, not applicable; IgG GPL, IgG phospholipid unit; IgM MPL, IgM phospholipid unit.
Values are range and mean ± SD unless otherwise noted.
The serological data are presented for the 20 patients NPSLE in whom data was available.
*
F-value instead of P-value because the test is ANCOVA (across all groups).
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